digital fluorescence microscope equipped with an nie-analysis soft image system (Nikon)
Nikon is a verified supplier 
90
Structured Review
Nikon
digital fluorescence microscope equipped with an nie-analysis soft image system
Digital Fluorescence Microscope Equipped With An Nie Analysis Soft Image System, supplied by Nikon, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/digital+fluorescence+microscope+equipped+with+an+nie-analysis+soft+image+system/pm37997385-62-22-26
Average 90 stars, based on 1 article reviews
Digital Fluorescence Microscope Equipped With An Nie Analysis Soft Image System, supplied by Nikon, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/digital+fluorescence+microscope+equipped+with+an+nie-analysis+soft+image+system/pm37997385-62-22-26
Average 90 stars, based on 1 article reviews
digital fluorescence microscope equipped with an nie-analysis soft image system - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Staining:Article Title: Actinomycin D Synergizes with Doxorubicin in Triple-Negative Breast Cancer by Inducing P53-Dependent Cell Apoptosis. Article Snippet: 1The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China 2Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 3Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China †These authors contributed equally to this work.. *Corresponding author: Tel: 010-63165313 Email: wjh@imm.ac.cn Saline:Article Title: Actinomycin D Synergizes with Doxorubicin in Triple-Negative Breast Cancer by Inducing P53-Dependent Cell Apoptosis. Article Snippet: 1The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China 2Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 3Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China †These authors contributed equally to this work.. *Corresponding author: Tel: 010-63165313 Email: wjh@imm.ac.cn Fluorescence:Article Title: Actinomycin D Synergizes with Doxorubicin in Triple-Negative Breast Cancer by Inducing P53-Dependent Cell Apoptosis. Article Snippet: 1The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China 2Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 3Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China †These authors contributed equally to this work.. *Corresponding author: Tel: 010-63165313 Email: wjh@imm.ac.cn Microscopy:Article Title: Actinomycin D Synergizes with Doxorubicin in Triple-Negative Breast Cancer by Inducing P53-Dependent Cell Apoptosis. Article Snippet: 1The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China 2Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 3Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China †These authors contributed equally to this work.. *Corresponding author: Tel: 010-63165313 Email: wjh@imm.ac.cn |